BRPI0417996A - agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular - Google Patents

agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular

Info

Publication number
BRPI0417996A
BRPI0417996A BRPI0417996-0A BRPI0417996A BRPI0417996A BR PI0417996 A BRPI0417996 A BR PI0417996A BR PI0417996 A BRPI0417996 A BR PI0417996A BR PI0417996 A BRPI0417996 A BR PI0417996A
Authority
BR
Brazil
Prior art keywords
agents
macular degeneration
diabetic retinopathy
formation
treating diabetic
Prior art date
Application number
BRPI0417996-0A
Other languages
English (en)
Inventor
Robert A Landers
David P Bingaman
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0417996A publication Critical patent/BRPI0417996A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"AGENTES PARA TRATAMENTO DE RETINOPATIA DIABéTICA E FORMAçãO DE GáNGLIOS EM DEGENERAçãO MACULAR". Agentes que estimulam a translocação nuclear de proteína Nrf2 e os aumentos subseqüentes em produtos genéticos que desintoxicam e eliminam metabólitos citotóxicos são providos em um método para tratar retinopatia diabética ou formação de drusas em degeneração macular relacionada com a idade. Os agentes estruturalmente diversos que atuam sobre a via Nrf2/ARE induzem a expressão de enzimas e proteínas que têm propriedades citoprotetoras quimicamente versáteis e são uma defesa contra metabólitos e xenobióticos tóxicos. Agentes incluem certos eletrófilos e oxidantes tais como um aceptor de Adição Michael, difenol, tiocarbamato, quinona, 1,2-ditiol-3-tiona, hidroxianisoóis butilados, flavonóide ou outra genisteina, um isotiocianato, 3,5-di-terc-butil-4-hidroxitolueno, etoxiquina, uma coumarina, combinações dos mesmos, ou um derivado ou análogo farmacologicamente ativo dos mesmos.
BRPI0417996-0A 2003-12-22 2004-12-17 agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular BRPI0417996A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53181103P 2003-12-22 2003-12-22
PCT/US2004/042562 WO2005063249A1 (en) 2003-12-22 2004-12-17 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration

Publications (1)

Publication Number Publication Date
BRPI0417996A true BRPI0417996A (pt) 2007-04-27

Family

ID=34738705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417996-0A BRPI0417996A (pt) 2003-12-22 2004-12-17 agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular

Country Status (9)

Country Link
US (2) US20050137147A1 (pt)
EP (1) EP1696926A1 (pt)
JP (1) JP2007515422A (pt)
AU (1) AU2004308911B2 (pt)
BR (1) BRPI0417996A (pt)
CA (1) CA2548146A1 (pt)
MX (1) MXPA06006862A (pt)
WO (1) WO2005063249A1 (pt)
ZA (1) ZA200605378B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE357932T1 (de) * 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
WO2006030907A1 (ja) * 2004-09-16 2006-03-23 Redox Bioscience Inc. 網膜保護剤
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
FR2902326B1 (fr) * 2006-06-20 2008-12-05 Oreal Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie
WO2008016095A1 (en) * 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20090324740A1 (en) * 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
EP2991621B1 (en) * 2013-05-02 2020-12-09 Retina Foundation of the Southwest Two-layer ocular implant
DK3381451T3 (da) * 2015-08-28 2025-10-06 Caliway Biopharmaceuticals Co Ltd Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
EP3919052A4 (en) * 2019-01-09 2022-10-05 Fuso Pharmaceutical Industries, Ltd. Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5681854A (en) * 1995-11-22 1997-10-28 Alcon Laboratories, Inc. Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
JP3719609B2 (ja) * 1995-12-21 2005-11-24 アルコン ラボラトリーズ，インコーポレイテッド 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
PT885888E (pt) * 1996-02-02 2003-12-31 Western Therapeutics Inst D Derivados e farmacos de isoquinolina
US6586425B2 (en) * 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
PT956865E (pt) * 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) * 1997-12-22 2002-08-27 Alcon Manufacturing, Ltd. 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US20010041174A1 (en) * 1998-11-24 2001-11-15 Najam Sharif Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
US6020383A (en) * 1999-01-11 2000-02-01 Eastman Chemicals Company Method for reducing blood cholesterol and/or blood triglycerides
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
AU2001271824A1 (en) * 2000-07-05 2002-01-14 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
GB0030727D0 (en) * 2000-12-15 2001-01-31 Lumitech Uk Ltd Methods and kits for detecting kinase activity
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US7199122B2 (en) * 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
AU2002335040A1 (en) * 2001-10-16 2003-04-28 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
US7407986B2 (en) * 2001-12-18 2008-08-05 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma

Also Published As

Publication number Publication date
MXPA06006862A (es) 2007-01-26
AU2004308911B2 (en) 2010-08-26
CA2548146A1 (en) 2005-07-14
US20050137147A1 (en) 2005-06-23
US20100204244A1 (en) 2010-08-12
ZA200605378B (en) 2008-01-30
JP2007515422A (ja) 2007-06-14
WO2005063249A1 (en) 2005-07-14
AU2004308911A1 (en) 2005-07-14
EP1696926A1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
BRPI0417987A (pt) agentes para o tratamento de retinopatia glaucomatosa e de neuropatia óptica
Uda et al. Induction of the anticarcinogenic marker enzyme, quinone reductase, in murine hepatoma cells in vitro by flavonoids
Hong et al. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BRPI0615145A2 (pt) derivados de xantina como agonistas hm74a seletivos
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
ATE280758T1 (de) Mittel zum schutz von nervenzellen
CY1112981T1 (el) Μεθοδος και συνθεση για την αγωγη της ρινιτιδας
UY26269A1 (es) Formulación de sal común y moxifloxacina
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
Huang et al. Inactivation of dengue virus by methylene blue/narrow bandwidth light system
EP1608395A4 (en) ANTICROPE WITH LK8 PROTEIN AS AN ACTIVE SUBSTANCE
WO2020024017A9 (en) Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
UY30042A1 (es) Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
BR0313186A (pt) Agente redutor de colesterol proveniente de fibra alimentar e substâncias redutoras de colesterol
PT1331940E (pt) Utilizacao da pentraxina longa ptx3 para o tratamento de doencas provocadas por uma activacao alterada do factor de crescimento fgf-2
ES2062570T3 (es) L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.